Sientra (SIEN) Misses Q4 EPS Views
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/2/2026
- Wall Street closes sharply lower as AI cash burn fears spark tech selloff
- Amazon burns cash, Intel flags weak PC demand as AI boom's costs ripple across markets
- Bitcoin, cryptocurrency prices fall after Binance reports security issue
- Higher yields now hurting AI stock bull as bond markets police capex: BofA
- Oil jumps 2%, settles at 6-month highs on fears of escalation in Iran
- Qualcomm shares fall on Intel warning and legal concerns
- Marvell Technology shares drop on Lumentum deal concerns
- Wall Street closes sharply lower as AI cash burn fears spark tech selloff
- Oracle shares drop on AI spending concerns and Microsoft criticism
- Cameco Q3 2026 earnings fall on lower Westinghouse income, higher costs
- After-Hours Movers: AMZN, TWLO, INTC, SNDK, RDDT, RBLX, PINS, RIVN, SBUX, ILMN
- After-Hours Movers: GOOGL, MSFT, NOW, KLAC. CMG, CVNA, TDOC
- After-Hours Movers: STX, ENPH, HOOD, V, CSGP, BOOM, CAKE, PPG, OI, TER
- After-Hours Movers: CLS, AVGO, CDNS, AMKR, WHR
- After-Hours Movers: WDC, BE, DECK, FIX, RNG
Sientra (SIEN) Acquires Rights to bioCorneum Silicone Gel Scar Management Therapy
March 9, 2016 4:22 PM ESTSientra, Inc. (NASDAQ: SIEN) today announced the acquisition from Enaltus, LLC of the exclusive U.S. rights to bioCorneum®, an advanced silicone gel scar management products, for $7.0 million in cash.
Jeffrey Nugent, Chairman and Chief Executive Officer of Sientra, said, Consistent with our stated business development objectives, this acquisition further leverages our highly experienced PSC sales force by adding a differentiated and complementary product that serves the needs of board-certified plastic surgeons while diversifying our business mix. We have received very positive feedback from our customers who are both current and potential... More



